Skip to main content

About

Aims and scope

Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. By offering a high-visibility forum for new insights and discussions, Translational Neurodegeneration creates a novel interface between the fields of basic, translational, and clinical research. It includes Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, motor neuron disease and other neurodegenerative diseases.

Topics of interest include but are not limited to the following areas of neurodegenerative diseases:

  • Epidemiology and pathogenesis
  • Research into diagnosis and prevention
  • Research into the disease pathogenesis
  • Development of new drugs and cell therapy
  • Drug delivery
  • Rehabilitation

Translational Neurodegeneration offers the opportunity for scientists, clinicians and physician-scientists to publish their research and clinical trials in a journal which is applicable to their specific field.

Open access

All articles published by Translational Neurodegeneration are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

As authors of articles published in Translational Neurodegeneration you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.

For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article processing charges (APC)

Authors who publish open access in Translational Neurodegeneration are required to pay an article processing charge (APC). The APC price will be determined from the date on which the article is accepted for publication.

The current APC, subject to VAT or local taxes where applicable, is: £2090.00/$2890.00/€2490.00

Visit our open access support portal and our Journal Pricing FAQs for further information.

Open access funding

Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.

Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.

Springer Nature offers APC waivers and discounts for articles published in our fully open access journals whose corresponding authors are based in the world’s lowest income countries (see our APC waivers and discounts policy for further information). Requests for APC waivers and discounts from other authors will be considered on a case-by-case basis, and may be granted in cases of financial need (see our open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.

Variable article-processing charges

In the case of Research highlights and Letters Translational Neurodegeneration levies an article-processing charge of Â£1440/$2040/€1735 for each article accepted for publication.


Indexing services

All articles published in Translational Neurodegeneration are included in:

  • CAS
  • DOAJ
  • MEDLINE
  • PubMed
  • PubMed Central
  • Science Citation Index Expanded
  • ​Scopus

The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.

Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.

Translational Neurodegeneration operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.

The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

Edited by Shengdi Chen, Translational Neurodegeneration is supported by an expert Editorial Board. Manuscripts are reviewed by internationally recognized experts in the field, selected in part from the journal's Editorial Board. The suitability of manuscripts for publication is assessed solely on criteria of scientific excellence: final decisions are made by the Editor-in-Chief and may include accept, reject, accept following minor revision and resubmit after major revision and further review.

Editorial policies

The editorial policies of Translational Neurodegeneration are determined jointly by its Editorial Board and Springer Nature in accordance with the legal and regulatory requirements of China. Unless otherwise stipulated in these guidelines, all manuscripts submitted to Translational Neurodegeneration should adhere to BioMed Central's editorial policies.

Citing articles in Translational Neurodegeneration

Articles in Translational Neurodegeneration should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Transl Neurodegener [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Transl Neurodegener 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Appeals and complaints

Authors who wish to appeal a rejection or make a complaint should follow the procedure outlined in the BMC Editorial Policies.

Benefits of publishing with BMC

High visibility

Translational Neurodegeneration's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. 

Speed of publication

Translational Neurodegeneration offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.

Flexibility

Online publication in Translational Neurodegeneration gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Translational Neurodegeneration are included in article alerts and regular email updates. Some may be highlighted on Translational Neurodegeneration’s pages and on the BMC homepage.

In addition, articles published in Translational Neurodegeneration may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Translational Neurodegeneration. A list of articles recently press-released by journals published by BMC is available here.

Copyright

As an author of an article published in Translational Neurodegeneration you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BMC license agreement).

For further information about the advantages of publishing in a journal from BMC, please click here.

Affiliated with

Annual Journal Metrics

  • 2022 Citation Impact
    12.6 - 2-year Impact Factor
    10.9 - 5-year Impact Factor
    2.072 - SNIP (Source Normalized Impact per Paper)
    2.571 - SJR (SCImago Journal Rank)

    2023 Speed
    8 days submission to first editorial decision for all manuscripts (Median)
    111 days submission to accept (Median)

    2023 Usage
    767,289 downloads
    3,389 Altmetric mentions